While actionable mutations are rare in patients with advanced disease, there are targeted agents that are approved for use in the space, explains Chung. For example, larotrectinib (Vitrakvi) was approved in November 2018 for the treatment of patients with solid tumors who harbor an NTRK fusion. Read more . . .
Vincent Chung, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, director of the Phase I Program, City of Hope, discusses the importance of genomic testing in pancreatic cancer.